The genomic landscape of advanced cancer.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Stool-based SDC2/SFRP2/TFPI2 methylation assay for colorectal neoplasia screening: a multicenter, case-control study.Frontiers in oncology · 2026
   Article
2. Genomic and microenvironmental heterogeneity shaping epithelial-to-mesenchymal trajectories in cancer.Nature communications · 2023
   Article
3. The significance of the fusion partner gene genomic neighborhood analysis in translocation-defined tumors.Molecular genetics & genomic medicine · 2022
   Article
4. Personalized medicine of non-gene-specific chemotherapies for non-small cell lung cancer.Acta pharmaceutica Sinica. B · 2021
   Review
5. A Detailed Catalogue of Multi-Omics Methodologies for Identification of Putative Biomarkers and Causal Molecular Networks in Translational Cancer Research.International journal of molecular sciences · 2021
   Review

Corrections and comments

• Comment on
  Pan-cancer analysis of advanced patient tumors reveals interactions between therapy and genomic landscapes.2020

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as